CEVIMELINE SHOULD BE ADMINISTERED WITH CAUTION TO PATIENTS TAKING BETA BLOCKERS, BECAUSE OF THE POSSIBILITY OF CONDUCTION DISTURBANCES. DRUGS WITH PARASYMPATHOMIMETIC EFFECTS ADMINISTERED CONCURRENTLY WITH CEVIMELINE CAN BE EXPECTED TO HAVE ADDITIVE EFFECTS. CEVIMELINE MIGHT INTERFERE WITH DESIRABLE ANTIMUSCARINIC EFFECTS OF DRUGS USED CONCOMITANTLY.
DRUGS WHICH INHIBIT CYP2D6 AND CYP3A3/4 ALSO INHIBIT THE METABOLISM OF CEVIMELINE. CEVIMELINE SHOULD BE USED WITH CAUTION IN INDIVIDUALS KNOWN OR SUSPECTED TO BE DEFICIENT IN CYP2D6 ACTIVITY, BASED ON PREVIOUS EXPERIENCE, AS THEY MAY BE AT A HIGHER RISK OF ADVERSE EVENTS.